Krystal Biotech (KRYS) Research & Development (2016 - 2026)

Krystal Biotech (KRYS) has 11 years of Research & Development data on file, last reported at $15.3 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 7.54% year-over-year to $15.3 million; the trailing twelve-month figure through Mar 2026 stood at $59.1 million (up 3.94% YoY), and the FY2025 full-year result was $58.0 million, up 8.33% from the prior year.
• Research & Development rose to $15.3 million in Q1 2026, from $14.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $15.6 million in Q2 2024 to a low of $9.3 million in Q1 2022.
• A 5-year average of $12.7 million and a median of $12.3 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development jumped 89.41% in 2022 and slipped 10.83% in 2024, its largest moves.
• Tracing KRYS's Research & Development over 5 years: stood at $10.7 million in 2022, then advanced by 5.87% to $11.4 million in 2023, then gained by 18.96% to $13.5 million in 2024, then gained by 9.36% to $14.8 million in 2025, then climbed by 3.63% to $15.3 million in 2026.
• Business Quant data shows KRYS's Research & Development at $15.3 million in Q1 2026, $14.8 million in Q4 2025, and $14.6 million in Q3 2025.